

Prosjektplan

2.utkast – 15.mai 2020

Navn: Sondre Helland Berg, Allette Steffensen Alværvik og Stine Kamilla Ommundsen

Intern veileder: Gry Sjøholt

1. Prosjektets tittel

Differential expression of microRNAs correlated to diabetic kidney disease. A literature review.

2. Bakgrunn, problemstilling

Vår oppgave blir å undersøke assosiasjonen til spesifikke mikroRNA hos utvalgte individer i en populasjonskohort med kroniske nyresykdommer i denne populasjonen. Nivå for utvalgte miRNA kvantifiseres ved hjelp av real-time PCR.

- **Problemstilling:**

“Is microRNA becoming the new biomarker for diabetic kidney disease?”

3. Material og metode

Materiale: Artikler fra litteratursøk (21 artikler – 14 tilgjengelige, 7 med abstrakt)

Metode: Litteraturstudie

4. Etiske betraktninger

Ingen etiske dilemmaer

5. Fremdriftsplan

- Uke 12: Levere 1.utkast av prosjektplan
- Uke 13:
 - Starte litteratursøk (finne ut: hva er kjent, hva er mindre kjent)
- Uke 14:
 - *Databehandling (utføre statistikkberegninger etc.)
 - Skrive metodikk
 - Prosessveiledning 1 (Går ut)
- Uke 15: **Påske**
 - Utregninger av datasett fra Tandi
 - Skrive videre om diabetes og PCR
- Uke 16:
 - Innsendt statusrapport 1 (13.april)
 - Prosessveiledning 2 – Møte med Turid tirsdag 14. april kl.15-16 (Zoom)
- Uke 17: Jobbe med relevante artikler
- Uke 18:
 - Underveis presentasjon tirsdag 28.april kl. 12.15 (obligatorisk)
 - Det ble tatt en avgjørelse på at datasett fra Tandi ikke skal brukes.
- Uke 19: Jobbe videre med resultat.
- Uke 20:
 - Prosessveiledning 3 med Turid
 - Jobbe med resultat og diskusjon
- Uke 22:
 - Ferdigstille bachelor
 - Innlevering av avhandling og Poster 29. Mai
 - Innlevering læringsutbytte og statusrapport
- Uke 24: Muntlig presentasjon/eksamen (zoom)

6. Ressurser

- Databaser:
 - **PubMed**: biomedisinsk litteratur fra MEDLINE, tidsvitenskapelige tidsskrifter og nettbøker.

7. Referanseliste

American Diabetes Association. (2013). Diagnosis and classification of diabetes mellitus. *Diabetes Care*, 36 Suppl 1, S67-74. <https://doi.org/10.2337/dc13-S067>

Badal, S. S., & Danesh, F. R. (2014). New insights into molecular mechanisms of diabetic kidney disease. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, 63(2 Suppl 2), S63-83. <https://doi.org/10.1053/j.ajkd.2013.10.047>

Beltrami, C., Simpson, K., Jesky, M., Wonnacott, A., Carrington, C., Holmans, P., Newbury, L., Jenkins, R., Ashdown, T., Dayan, C., Satchell, S., Corish, P., Cockwell, P., Fraser, D., & Bowen, T. (2018). Association of Elevated Urinary miR-126, miR-155, and miR-29b with Diabetic Kidney Disease. *The American Journal of Pathology*, 188(9), 1982–1992. <https://doi.org/10.1016/j.ajpath.2018.06.006>

Bolignano, D., & Zoccali, C. (2017). Non-proteinuric rather than proteinuric renal diseases are the leading cause of end-stage kidney disease. *Nephrology Dialysis Transplantation*, 32(suppl_2), ii194–ii199. <https://doi.org/10.1093/ndt/gfw440>

Califf, R. M. (2018). Biomarker definitions and their applications. *Experimental Biology and Medicine (Maywood, N.J.)*, 243(3), 213–221. <https://doi.org/10.1177/1535370217750088>

Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., Rassenti, L., Kipps, T., Negrini, M., Bullrich, F., & Croce, C. M. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, 99(24), 15524–15529. <https://doi.org/10.1073/pnas.242606799>

Cao, Q., Chen, X.-M., Huang, C., & Pollock, C. A. (2019). MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update. *FASEB BioAdvances*, 1(6), 375–388. <https://doi.org/10.1096/fba.2018-00064>

Cardenas-Gonzalez, M., Srivastava, A., Pavkovic, M., Bijol, V., Rennke, H. G., Stillman, I. E., Zhang, X., Parikh, S., Rovin, B. H., Afkarian, M., de Boer, I. H., Himmelfarb, J., Waikar, S. S., & Vaidya, V. S. (2017). Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy. *Clinical Chemistry*, 63(9), 1515–1526. <https://doi.org/10.1373/clinchem.2017.274175>

Chien, H.-Y., Chen, C.-Y., Chiu, Y.-H., Lin, Y.-C., & Li, W.-C. (2016). Differential microRNA Profiles Predict Diabetic Nephropathy Progression in Taiwan. *International Journal of Medical Sciences*, 13(6), 457–465. <https://doi.org/10.7150/ijms.15548>

Delić, D., Eisele, C., Schmid, R., Baum, P., Wiech, F., Gerl, M., Zimdahl, H., Pullen, S. S., & Urquhart, R. (2016). Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients. *PloS One*, 11(3), e0150154. <https://doi.org/10.1371/journal.pone.0150154>

- Eissa, S., Matboli, M., Aboushahba, R., Bekhet, M. M., & Soliman, Y. (2016). Urinary exosomal microRNA panel unravels novel biomarkers for diagnosis of type 2 diabetic kidney disease. *Journal of Diabetes and Its Complications*, 30(8), 1585–1592. <https://doi.org/10.1016/j.jdiacomp.2016.07.012>
- Eissa, S., Matboli, M., & Bekhet, M. M. (2016). Clinical verification of a novel urinary microRNA panel: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis. *Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie*, 83, 92–99. <https://doi.org/10.1016/j.biopha.2016.06.018>
- El-Samahy, M. H., Adly, A. A., Elhenawy, Y. I., Ismail, E. A., Pessar, S. A., Mowafy, M. E.-S., Saad, M. S., & Mohammed, H. H. (2018). Urinary miRNA-377 and miRNA-216a as biomarkers of nephropathy and subclinical atherosclerotic risk in pediatric patients with type 1 diabetes. *Journal of Diabetes and Its Complications*, 32(2), 185–192. <https://doi.org/10.1016/j.jdiacomp.2017.10.014>
- Esquela-Kerscher, A. (2014). The lin-4 microRNA: The ultimate micromanager. *Cell Cycle (Georgetown, Tex.)*, 13(7), 1060–1061. <https://doi.org/10.4161/cc.28384>
- Fouad, M., Salem, I., Elhefnawy, K., Raafat, N., & Faisal, A. (2020). MicroRNA-21 as an Early Marker of Nephropathy in Patients with Type 1 Diabetes. *Indian Journal of Nephrology*, 30(1), 21–25. https://doi.org/10.4103/ijn.IJN_80_19
- Ghai, V., Wu, X., Bheda-Malge, A., Argyropoulos, C. P., Bernardo, J. F., Orchard, T., Galas, D., & Wang, K. (2018). Genome-wide Profiling of Urinary Extracellular Vesicle microRNAs Associated With Diabetic Nephropathy in Type 1 Diabetes. *Kidney International Reports*, 3(3), 555–572. <https://doi.org/10.1016/j.ekir.2017.11.019>
- Griffiths-Jones, S., Grocock, R. J., Dongen, S. van, Bateman, A., & Enright, A. J. (2006). miRBase: MicroRNA sequences, targets and gene nomenclature. *Oxford University Press*, 34(Nucleic Acids Research). <https://doi.org/10.1093/nar/gkj112>
- Jia, Y., Guan, M., Zheng, Z., Zhang, Q., Tang, C., Xu, W., Xiao, Z., Wang, L., & Xue, Y. (2016). MiRNAs in Urine Extracellular Vesicles as Predictors of Early-Stage Diabetic Nephropathy. *Journal of Diabetes Research*, 2016, 7932765. <https://doi.org/10.1155/2016/7932765>
- Kato, M., & Natarajan, R. (2014). Diabetic nephropathy—Emerging epigenetic mechanisms. *Nature Reviews. Nephrology*, 10(9), 517–530. <https://doi.org/10.1038/nrneph.2014.116>
- Li, W., Yang, S., Qiao, R., & Zhang, J. (2018). Potential Value of Urinary Exosome-Derived let-7c-5p in the Diagnosis and Progression of Type II Diabetic Nephropathy. *Clinical Laboratory*, 64(5), 709–718. <https://doi.org/10.7754/Clin.Lab.2018.171031>
- Linse, K. D. (2013, April 11). *How can MicroRNAs be described?* Bio-Synthesis, Inc. <https://blog-biosyn.com/2013/04/11/how-can-micrornas-be-described/>
- Lu, T. X., & Rothenberg, M. E. (2018). MicroRNA. *The Journal of Allergy and Clinical Immunology*, 141(4), 1202–1207. <https://doi.org/10.1016/j.jaci.2017.08.034>
- Milas, O., Gadalean, F., Vlad, A., Dumitrascu, V., Gluhovschi, C., Gluhovschi, G., Velciov, S., Popescu, R., Bob, F., Matusz, P., Pusztai, A.-M., Cretu, O. M., Secara, A., Simulescu, A., Ursoniu, S., Vlad, D., & Petrica, L. (2018). Deregulated profiles of urinary microRNAs may explain podocyte injury and proximal tubule dysfunction in normoalbuminuric patients with type 2 diabetes mellitus. *Journal of Investigative Medicine: The Official Publication of the American Federation for Clinical Research*, 66(4), 747–754. <https://doi.org/10.1136/jim-2017-000556>

- Nascimento, L. R. do, & Domingueti, C. P. (2019). MicroRNAs: New biomarkers and promising therapeutic targets for diabetic kidney disease. *Jornal Brasileiro De Nefrologia: 'Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia*, 41(3), 412–422. <https://doi.org/10.1590/2175-8239-JBN-2018-0165>
- National Institute of Diabetes and Digestive and Kidney Diseases. (2017, February). *Diabetic Kidney disease*. U.S. Department of Health and Human Services. <https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease>
- Peng, H., Zhong, M., Zhao, W., Wang, C., Zhang, J., Liu, X., Li, Y., Paudel, S. D., Wang, Q., & Lou, T. (2013). Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients. *PLoS One*, 8(12), e82607. <https://doi.org/10.1371/journal.pone.0082607>
- Petrica, L., Puszta, A.-M., Vlad, M., Vlad, A., Gadalean, F., Dumitrescu, V., Vlad, D., Velciov, S., Gluhovschi, C., Bob, F., Ursoniu, S., Petrica, M., Matusz, P., Cretu, O., Radu, D., Milas, O., Secara, A., Simulescu, A., Popescu, R., & Jianu, D. C. (2020). MiRNA Expression is Associated with Clinical Variables Related to Vascular Remodeling in the Kidney and the Brain in Type 2 Diabetes Mellitus Patients. *Endocrine Research*, 45(2), 119–130. <https://doi.org/10.1080/07435800.2019.1690505>
- Prabu, P., Rome, S., Sathishkumar, C., Gastebois, C., Meugnier, E., Mohan, V., & Balasubramanyam, M. (2019). MicroRNAs from urinary extracellular vesicles are non-invasive early biomarkers of diabetic nephropathy in type 2 diabetes patients with the ‘Asian Indian phenotype’. *Diabetes & Metabolism*, 45(3), 276–285. <https://doi.org/10.1016/j.diabet.2018.08.004>
- Pritchard, C. C., Cheng, H. H., & Tewari, M. (2012). MicroRNA profiling: Approaches and considerations. *Nature Reviews. Genetics*, 13(5), 358–369. <https://doi.org/10.1038/nrg3198>
- Regmi, A., Liu, G., Zhong, X., Hu, S., Ma, R., Gou, L., Zafar, M. I., & Chen, L. (2019). Evaluation of Serum microRNAs in Patients with Diabetic Kidney Disease: A Nested Case-Controlled Study and Bioinformatics Analysis. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, 25, 1699–1708. <https://doi.org/10.12659/MSM.913265>
- Shao, Y., Ren, H., Lv, C., Ma, X., Wu, C., & Wang, Q. (2017). Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease. *Endocrine*, 55(1), 130–138. <https://doi.org/10.1007/s12020-016-1069-4>
- Simpson, K., Wonnacott, A., Fraser, D. J., & Bowen, T. (2016). MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy. *Current Diabetes Reports*, 16(3), 35. <https://doi.org/10.1007/s11892-016-0724-8>
- Sun, I. O., & Lerman, L. O. (2019). Urinary microRNA in kidney disease: Utility and roles. *American Journal of Physiology. Renal Physiology*, 316(5), F785–F793. <https://doi.org/10.1152/ajprenal.00368.2018>
- Wang, H., Ach, R. A., & Curry, B. (2007). Direct and sensitive miRNA profiling from low-

- input total RNA. *RNA (New York, N.Y.)*, 13(1), 151–159. <https://doi.org/10.1261/rna.234507>
- Wright, M. W., & Bruford, E. A. (2011). Naming ‘junk’: Human non-protein coding RNA (ncRNA) gene nomenclature. *Human Genomics*, 5(2), 90–98. <https://doi.org/10.1186/1479-7364-5-2-90>
- Xie, Y., Jia, Y., Cuihua, X., Hu, F., Xue, M., & Xue, Y. (2017). Urinary Exosomal MicroRNA Profiling in Incipient Type 2 Diabetic Kidney Disease. *Journal of Diabetes Research*, 2017, 6978984. <https://doi.org/10.1155/2017/6978984>
- Yang, X., Liu, S., Zhang, R., Sun, B., Zhou, S., Chen, R., & Yu, P. (2017). Micrornucleic acid-192 as a specific biomarker for the early diagnosis of diabetic kidney disease. *Journal of Diabetes Investigation*. <https://doi.org/10.1111/jdi.12753>
- Zang, J., Maxwell, A. P., Simpson, D. A., & McKay, G. J. (2019). Differential Expression of Urinary Exosomal MicroRNAs miR-21-5p and miR-30b-5p in Individuals with Diabetic Kidney Disease. *Scientific Reports*, 9(1), 10900. <https://doi.org/10.1038/s41598-019-47504-x>
- Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J., & Mi, S. (2015). Exosome and exosomal microRNA: Trafficking, sorting, and function. *Genomics, Proteomics & Bioinformatics*, 13(1), 17–24. <https://doi.org/10.1016/j.gpb.2015.02.001>
- Zhang, L., Li, R., He, J., Yang, Q., Wu, Y., Huang, J., & Wu, B. (2017). Co-expression analysis among microRNAs, long non-coding RNAs, and messenger RNAs to understand the pathogenesis and progression of diabetic kidney disease at the genetic level. *Methods (San Diego, Calif.)*, 124, 46–56. <https://doi.org/10.1016/j.ymeth.2017.05.023>

8. Vedlegg

Ingen vedlegg i denne bacheloren.